PON1 multitasks to protect health

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 12639-12640

  Chambers, Janice E ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIMPYLATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSINE; ORGANOPHOSPHATE INSECTICIDE; PARAOXON; PARATHION;

ACCIDENTAL INJURY; ACUTE TOXICITY; AGRICULTURAL WORKER; CATALYSIS; CHEMICAL WARFARE; CHOLINERGIC ACTIVITY; CHOLINESTERASE INHIBITION; DETOXIFICATION; ENZYME ENGINEERING; ENZYME INHIBITION; ENZYME SUBSTRATE; ESCHERICHIA COLI; NONHUMAN; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; RABBIT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; HEALTH; HUMANS; MICE; PHOSPHORIC ACID ESTERS; RECOMBINANT PROTEINS;

EID: 51349132496     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807062105     Document Type: Note

References (11)

1. Gaidukov L, Rosenblat M, Aviram M, Tawfik D (2006) The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 47:2492-2502.
2. Stevens RC, et al. (2008) Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci USA 105:12780-12784.
3. Meister RT, ed (2004) Crop Protection Handbook (MeisterPRO Information Resources, Willoughby, OH).
4. Pond AL, Chambers HW, Coyne CP, Chambers JE (1998) Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon. J Pharmacol Exp Ther 286:1404-1411.
5. Mertens A, Holvoet P (2001) Oxidized LDL and HDL: Antagonists in atherothrombosis. FASEB J 15:2073-2084.
6. Watson AD, et al. (1995) Protective effect of high-density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low-density lipoprotein. J Clin Invest 96:2882-2891.
7. Davies H, et al. (1996) The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
8. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JW (2003) Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 111:1403-1409.
9. Richter RJ, Furlong CE (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-753.
10. Costa LG, Cole TB, Jarvik GP, Furlong CE (2003) Functional genomics of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54:371-392.
11. Miyaki K, et al. (2005) Effects of sarin on the nervous system of subway workers seven years after the Tokyo subway sarin attack. J Occup Health 47:299-304.